论文部分内容阅读
近年来,慢性肺部疾病的发病率和病死率都有明显上升。世界卫生组织的Lopez等[1]调查显示,慢性阻塞性肺疾病(COPD)于2002年居常见死亡原因的11位,预计至2030年该病上升成为第4位。目前临床上普遍采用常规治疗,但由于疾病本身特点,导致这类疾病的治疗进展缓慢。随着干细胞研究的深入,其在肺损伤修复中作用的认识也在不断加深。大量研究表明,诱导植入体内的成体干细胞可以向包括肺组织在内的多种非造血细胞类型分化[2-3],从而给慢性肺疾病的治疗另辟蹊径。
In recent years, the incidence of chronic lung disease and mortality have increased significantly. According to the World Health Organization’s survey by Lopez et al. [1], COPD was the 11 most common cause of death in 2002 and it is estimated that the disease will rise to No. 4 by 2030. At present, the conventional treatment is generally used in clinical practice, but due to the characteristics of the disease itself, the treatment of such diseases is progressing slowly. With the deepening of stem cell research, its understanding of the role of lung injury repair is also deepening. Numerous studies have shown that induction of adult stem cells into the body can differentiate into a variety of non-hematopoietic cell types, including lung tissue [2-3], which leads to a new approach to the treatment of chronic lung diseases.